Cargando…
Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
Although vaccines are currently used to control the coronavirus disease 2019 (COVID‐19) pandemic, treatment options are urgently needed for those who cannot be vaccinated and for future outbreaks involving new severe acute respiratory syndrome coronavirus virus 2 (SARS‐CoV‐2) strains or coronaviruse...
Autores principales: | Chiu, Winston, Verschueren, Lore, Van den Eynde, Christel , Buyck, Christophe, De Meyer, Sandra, Jochmans, Dirk, Bojkova, Denisa, Ciesek, Sandra, Cinatl, Jindrich, De Jonghe, Steven, Leyssen, Pieter, Neyts, Johan, Van Loock, Marnix, Van Damme, Ellen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088669/ https://www.ncbi.nlm.nih.gov/pubmed/35229317 http://dx.doi.org/10.1002/jmv.27683 |
Ejemplares similares
-
In vitro activity of itraconazole against SARS‐CoV‐2
por: Van Damme, Ellen, et al.
Publicado: (2021) -
Lack of antiviral activity of darunavir against SARS-CoV-2
por: De Meyer, Sandra, et al.
Publicado: (2020) -
Identification of Z-Tyr-Ala-CHN(2), a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2
por: Doijen, Jordi, et al.
Publicado: (2023) -
Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication
por: Klann, Kevin, et al.
Publicado: (2020) -
SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)